Search

Incyte Corp

Ouvert

SecteurSoins de santé

127.66 2.32

Résumé

Variation du prix de l'action

24h

Actuel

Min

124.61

Max

127.6

Chiffres clés

By Trading Economics

Revenu

282M

586M

Ventes

401M

1.7B

P/E

Moyenne du Secteur

15.566

56.432

BPA

2.8

Marge bénéficiaire

34.982

Employés

2,844

EBITDA

384M

752M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+4.84% upside

Dividendes

By Acuity

Prochains Résultats

27 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1B

25B

Ouverture précédente

125.34

Clôture précédente

127.66

Sentiment de l'Actualité

By Acuity

40%

60%

97 / 339 Classement par Healthcare

Incyte Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 sept. 2026, 23:06 UTC

Incyte Corp is trading lower in after-market hours, marking its lowest point since the market closed and remaining below its 20-day moving average.

15 sept. 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours, reflecting broader market fluctuations and remaining below the 20-day moving average.

14 sept. 2026, 20:08 UTC

Incyte Corp's shares are higher amid overall market gains, despite earlier volatility. Broader market concerns include rising crude oil prices and inflation.

11 sept. 2026, 22:01 UTC

Incyte Corp shares are higher in after-market trading, despite a decline in consumer sentiment reflected by the Michigan Consumer Sentiment Index.

10 sept. 2026, 19:36 UTC

Event
News

Incyte's MINJUVI receives funding in Ontario for lymphoma treatment. Shares are lower despite this development, currently trading below their 20-day moving average.

9 sept. 2026, 19:07 UTC

Event
Social Media

Incyte Corp gains amid positive sentiment for its upcoming PDUFA date for Zilurgisertib, scheduled for September 26, despite earlier session volatility.

8 sept. 2026, 20:02 UTC

News

Incyte Corp shares are lower today, driven by a downturn in the Biotechnology sub-sector. Analysts maintain a consensus "Moderate Buy" rating on the stock.

4 sept. 2026, 23:55 UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

3 sept. 2026, 19:16 UTC

Incyte Corp shares are lower amid broader market declines influenced by rising jobless claims. The stock remains above its 20-day moving average.

2 sept. 2026, 23:16 UTC

Incyte Corp shares are trading higher in after-market hours, amid a weaker-than-expected ADP payrolls report that may influence Federal Reserve interest rate decisions.

1 sept. 2026, 22:06 UTC

Incyte Corp shares are higher in after-market hours, though no specific news explains the movement. Broader market pressures persist from rising bond yields.

31 août 2026, 20:04 UTC

News

Incyte Corp shares are lower amid broader market weakness following comments from Warsh at the Jackson Hole Economic Symposium on inflation and monetary policy.

28 août 2026, 23:21 UTC

News

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

27 août 2026, 20:07 UTC

News

Incyte Corp shares are lower today, reflecting broader market declines. Analysts from TD Cowen upgraded the stock to a strong buy amid ongoing positive sentiment.

26 août 2026, 19:36 UTC

Incyte Corp shares are lower during Wednesday's session, having reached a session low earlier. No specific news was identified to explain the price movement.

25 août 2026, 23:21 UTC

Incyte Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by a decline in crude oil prices and easing treasury yields.

24 août 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

21 août 2026, 19:46 UTC

News

Incyte Corp's stock is higher today, supported by President Pablo J. Cagnoni's recent sale of 10,801 shares at $125.56. The stock remains near its one-month high.

20 août 2026, 23:41 UTC

Incyte Corp shares are higher in after-market trading, recovering from a slight dip and positioned above the 20-day moving average. No specific news was identified.

19 août 2026, 23:01 UTC

Incyte Corp shares declined in after-hours trading, pulling back from earlier gains. The stock remains above its 20-day moving average and near a one-month high.

17 août 2026, 20:06 UTC

News

Piper Sandler raised Incyte Corp's price target to $130 from $110, contributing to the stock's upward movement after four days of declines.

14 août 2026, 19:36 UTC

Incyte Corp shares are lower, continuing a recent decline amid concerns over July retail sales, which fell 0.6% against expectations for growth.

13 août 2026, 23:26 UTC

Incyte Corp shares are lower in after-market hours, despite broader market gains from reduced Federal Reserve rate hike expectations. No specific news was identified.

10 août 2026, 19:36 UTC

Incyte Corp shares are higher today, maintaining an upward trend since Friday. The stock remains above its 20-day moving average, reflecting solid performance.

6 août 2026, 19:44 UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

5 août 2026, 19:56 UTC

Incyte Corp shares are lower today, retracing from earlier session gains. No specific news was identified to explain the decline.

4 août 2026, 19:46 UTC

News

Mizuho raised its price target on Incyte Corp to $137, maintaining an Outperform rating. Analyst Josh Brown's comments on CNBC contributed to positive sentiment today.

3 août 2026, 23:56 UTC

Incyte Corp shares are higher in after-market hours, recovering from five consecutive daily declines. Broader market sentiment remains positive amid declining oil prices.

31 juil. 2026, 22:21 UTC

Incyte Corp's shares are higher in after-market trading, driven by a rise in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

30 juil. 2026, 23:56 UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of declines since Thursday's close amid broader market pressures.

Comparaison

Variation de prix

Incyte Corp prévision

Objectif de Prix

By TipRanks

4.84% hausse

Prévisions sur 12 Mois

Moyen 130.789 USD  4.84%

Haut 155 USD

Bas 104 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

21 ratings

11

Achat

10

Maintien

0

Vente

Sentiment

By Acuity

97 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat